Medivation Inc (MDVN) : Anandar Capital Management Lp added new position in Medivation Inc during the most recent quarter end. The investment management firm now holds 100,000 shares of Medivation Inc which is valued at $6,602,000 , the company said in a statement filed on Aug 12, 2016 with the SEC.Medivation Inc makes up approximately 5.04% of Anandar Capital Management Lp’s portfolio.
Other Hedge Funds, Including , Riverhead Capital Management sold out all of its stake in MDVN during the most recent quarter. The investment firm sold 18,525 shares of MDVN which is valued $1,223,021. Globeflex Capital L P sold out all of its stake in MDVN during the most recent quarter. The investment firm sold 51,108 shares of MDVN which is valued $3,374,150.Edmond De Rothschild Asset Management (france) reduced its stake in MDVN by selling 192,100 shares or 41.57% in the most recent quarter. The Hedge Fund company now holds 270,000 shares of MDVN which is valued at $17,825,400. Medivation Inc makes up approx 0.80% of Edmond De Rothschild Asset Management (france)’s portfolio.Bnp Paribas Investment Partners S.a. reduced its stake in MDVN by selling 663,932 shares or 62.36% in the most recent quarter. The Hedge Fund company now holds 400,763 shares of MDVN which is valued at $26,290,053. Medivation Inc makes up approx 0.22% of Bnp Paribas Investment Partners S.a.’s portfolio.Stephens Inc Ar reduced its stake in MDVN by selling 7 shares or 9.72% in the most recent quarter. The Hedge Fund company now holds 65 shares of MDVN which is valued at $4,111.
Medivation Inc closed down -0.07 points or -0.09% at $80.28 with 58,01,882 shares getting traded on Monday. Post opening the session at $80.3, the shares hit an intraday low of $80.26 and an intraday high of $80.34 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $0.26. The company had revenue of $206.20 million for the quarter, compared to analysts expectations of $209.92 million. The company’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.
Many Wall Street Analysts have commented on Medivation Inc. Medivation Inc was Downgraded by Stifel to ” Hold” on Aug 23, 2016. Medivation Inc was Downgraded by Credit Suisse to ” Neutral” on Aug 23, 2016. Company shares were Downgraded by Maxim Group on Aug 23, 2016 to ” Hold”, Firm has raised the Price Target to $ 81.50 from a previous price target of $76 .
Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.